Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Advanced Chart

Key Stats

Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DRNA Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
DRNA Jan 2022 22.500 call
DRNA Jul 2022 40.000 call(CONTR
See More Headlines

DRNA Stock Analysis - Frequently Asked Questions

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company earned $62.95 million during the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

Last Earnings
11/09/2021
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRNA
Employees
302
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-112,750,000.00
Pretax Margin
-63.82%

Debt

Sales & Book Value

Annual Sales
$164.31 million
Price / Cash Flow
N/A
Book Value
$1.84 per share
Price / Book
20.77

Miscellaneous

Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DRNA) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners